PURPOSE: This phase I study evaluated the effect of folate supplementation on the toxicity, tolerability, and pharmacokinetics of pemetrexed in patients with locally advanced or metastatic cancer. It also examined two different types of vitamin supplementation and whether the extent of prior myelosuppressive therapy affected pemetrexed tolerability. PATIENTS AND METHODS: Patients received a 10-min infusion of 600 to 14,00 mg/m(2) pemetrexed every 3 weeks. Patients were stratified into cohorts by pretreatment status [lightly pretreated (LPT) or heavily pretreated (HPT)] and were supplemented with intermittent high-dose folic acid (HDFA) or with continuous daily multivitamins (MVI) containing nutritional doses of folic acid. Pemetrexed plasma pharmacokinetics were evaluated for cycle 1. RESULTS: Sixty-two HDFA patients (28 HPT and 34 LPT) were treated with 204 cycles of pemetrexed, and 43 MVI patients (20 HPT and 23 LPT) were treated with 182 cycles. Hematologic dose-limiting toxicities included grade 4 neutropenia (5 of 105 patients), grade 4 thrombocytopenia (4 of 105 patients), and febrile neutropenia (3 of 105 patients). Nonhematologic toxicities included fatigue, vomiting, diarrhea, and nausea. Pemetrexed doses of 800 and 1,050 mg/m(2) were well tolerated when administered with vitamin supplementation to HPT and LPT patients, respectively. There were no clinically relevant differences in toxicities or pemetrexed pharmacokinetics for LPT versus HPT patients or for patients receiving HDFA versus daily MVI supplementation. CONCLUSIONS: The pemetrexed doses tolerated in this study with vitamin supplementation were significantly higher than those tolerated in earlier studies without supplementation, and toxicities were independent of the type of vitamin supplementation or prior myelosuppressive treatment. The recommended dose of pemetrexed is 1,050 mg/m(2) in LPT patients and 800 mg/m(2) in HPT patients, irrespective of the type of vitamin supplementation.
PURPOSE: This phase I study evaluated the effect of folate supplementation on the toxicity, tolerability, and pharmacokinetics of pemetrexed in patients with locally advanced or metastatic cancer. It also examined two different types of vitamin supplementation and whether the extent of prior myelosuppressive therapy affected pemetrexed tolerability. PATIENTS AND METHODS: Patients received a 10-min infusion of 600 to 14,00 mg/m(2) pemetrexed every 3 weeks. Patients were stratified into cohorts by pretreatment status [lightly pretreated (LPT) or heavily pretreated (HPT)] and were supplemented with intermittent high-dose folic acid (HDFA) or with continuous daily multivitamins (MVI) containing nutritional doses of folic acid. Pemetrexed plasma pharmacokinetics were evaluated for cycle 1. RESULTS: Sixty-two HDFA patients (28 HPT and 34 LPT) were treated with 204 cycles of pemetrexed, and 43 MVI patients (20 HPT and 23 LPT) were treated with 182 cycles. Hematologic dose-limiting toxicities included grade 4 neutropenia (5 of 105 patients), grade 4 thrombocytopenia (4 of 105 patients), and febrile neutropenia (3 of 105 patients). Nonhematologic toxicities included fatigue, vomiting, diarrhea, and nausea. Pemetrexed doses of 800 and 1,050 mg/m(2) were well tolerated when administered with vitamin supplementation to HPT and LPT patients, respectively. There were no clinically relevant differences in toxicities or pemetrexed pharmacokinetics for LPT versus HPT patients or for patients receiving HDFA versus daily MVI supplementation. CONCLUSIONS: The pemetrexed doses tolerated in this study with vitamin supplementation were significantly higher than those tolerated in earlier studies without supplementation, and toxicities were independent of the type of vitamin supplementation or prior myelosuppressive treatment. The recommended dose of pemetrexed is 1,050 mg/m(2) in LPT patients and 800 mg/m(2) in HPT patients, irrespective of the type of vitamin supplementation.
Authors: Setsuko K Chambers; H-H Sherry Chow; Mike F Janicek; Janiel M Cragun; Kenneth D Hatch; Haiyan Cui; Cynthia Laughren; Mary C Clouser; Janice L Cohen; Heather M Wright; Nisreen Abu Shahin; David S Alberts Journal: Clin Cancer Res Date: 2012-03-15 Impact factor: 12.531
Authors: Nikki de Rouw; Berber Piet; Hieronymus J Derijks; Michel M van den Heuvel; Rob Ter Heine Journal: Drug Saf Date: 2021-11-06 Impact factor: 5.606
Authors: Isam Abdel-Karim; William K Plunkett; Susan O'Brien; Francis Giles; Deborah Thomas; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Min Du; Karen B Schneck; Victor J Chen; Boris K Lin; Steven J Nicol; Hagop M Kantarjian Journal: Invest New Drugs Date: 2010-01-21 Impact factor: 3.850
Authors: Allen L Cohn; J William Myers; Steven Mamus; Charles Deur; Steven Nicol; Karen Hood; Muhammad M Khan; Des Ilegbodu; Lina Asmar Journal: Invest New Drugs Date: 2008-02-28 Impact factor: 3.850
Authors: David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544
Authors: Nikki de Rouw; Hieronymus J Derijks; Luuk B Hilbrands; René J Boosman; Berber Piet; Stijn L W Koolen; Jacobus A Burgers; Anne-Marie C Dingemans; Michel M van den Heuvel; Lizza E L Hendriks; Joachim G J V Aerts; Sander Croes; Ron H J Mathijssen; Alwin D R Huitema; David M Burger; Bonne Biesma; Rob Ter Heine Journal: Br J Clin Pharmacol Date: 2021-08-26 Impact factor: 3.716